Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
118.45
+0.99 (+0.84%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
December 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Supports Hiring Our Heroes Corporate Fellowship Program
December 06, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
December 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Fighting for Health Equity From Inside the Health Care Industry
December 03, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
December 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Creating a New World in Minecraft for Students to Explore
December 01, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces First-Quarter 2022 Dividend
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Acquisition of Acceleron Pharma Inc.
November 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
November 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
We're Training More Diverse Investigators to Help Improve Clinical Trials
November 17, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Seramount Names Merck As One of the 2021 Best Companies for Dads
November 12, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Economy
Exposures
COVID-19
Interest Rates
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
November 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
November 09, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
November 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
November 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the...
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
The $11 Trillion Healthcare Industry Is About To Change Forever
November 04, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government...
Via
FinancialNewsMedia
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
November 04, 2021
From
Merck & Co., Inc.
Via
Business Wire
The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries
November 01, 2021
SOURCE: Merck & Co., Inc.
Via
3BL Media
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
November 03, 2021
Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...
Via
FinancialNewsMedia
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.